Note 21 - Segments (Tables)

12 Months Ended

Dec. 31, 2017

Year Ended December 31, 2017	Diagnostics			Therapeutics			Corporate			Total
Tc99m tilmanocept sales revenue:
United States	$	—		$	—		$	—		$	—
International		—			—			—			—
Tc99m tilmanocept license revenue		100,000			—			—			100,000
Tc99m tilmanocept royalty revenue		9,126			—			—			9,126
Grant and other revenue		1,506,232			195,079			—			1,701,311
Total revenue		1,615,358			195,079			—			1,810,437
Cost of goods sold		3,651			—			—			3,651
Research and development expenses, excluding depreciation and amortization		3,784,255			729,587			—			4,513,842
Selling, general and administrative expenses, excluding depreciation and amortization (a)		—			34,484			10,895,301			10,929,785
Depreciation and amortization (b)		—			—			240,166			240,166
L oss from operations (c)		(2,172,548	)		(568,992	)		(11,135,467	)		(13,877,007	)
Other income (expense) (d)		—			—			(3,912,679	)		(3,912,679	)
Benefit from income taxes		496,127			129,936			3,436,426			4,062,489
L oss from continuing operations		(1,676,421	)		(439,056	)		(11,611,720	)		(13,727,197	)
Income from discontinued operations, net of tax effect		88,673,053			—			—			88,673,053
Net income (loss)		86,996,632			(439,056	)		(11,611,720	)		74,945,856
Total assets, net of depreciation and amortization:
United States	$	13,065,871		$	49,001		$	7,634,237		$	20,749,109
International		30,476			—			1,851			32,327
Capital expenditures		—			—			33,690			33,690

Year Ended December 31, 2016	Diagnostics			Therapeutics			Corporate			Total
Tc99m tilmanocept sales revenue:
United States	$	—		$	—		$	—		$	—
International		39,601			—			—			39,601
Tc99m tilmanocept license revenue		1,795,625			—			—			1,795,625
Grant and other revenue		3,011,642			124,766			—			3,136,408
Total revenue		4,846,868			124,766			—			4,971,634
Cost of goods sold, excluding depreciation and amortization		62,260			—			—			62,260
Research and development expenses, excluding depreciation and amortization		6,375,929			762,151			—			7,138,080
Selling, general and administrative expenses, excluding depreciation and amortization (a)		—			63,158			7,403,329			7,466,487
Depreciation and amortization (b)		56,317			—			397,232			453,549
L oss from operations (c)		(1,647,638	)		(700,543	)		(7,800,561	)		(10,148,742	)
Other income (expense), excluding equity in the loss of R-NAV, LLC (d)		—			—			2,786,007			2,786,007
Equity in the loss of R-NAV, LLC		—			—			(15,159	)		(15,159	)
L oss from continuing operations		(1,647,638	)		(700,543	)		(5,029,713	)		(7,377,894	)
Loss from discontinued operations, net of tax effect		(6,931,137	)		—			—			(6,931,137	)
Net loss		(8,578,775	)		(700,543	)		(5,029,713	)		(14,309,031	)
Total assets, net of depreciation and amortization:
United States	$	3,815,271		$	15,075		$	8,498,797		$	12,329,143
International		131,752			—			781			132,533
Capital expenditures		—			—			1,847			1,847

Year Ended December 31, 2015	Diagnostics			Therapeutics			Corporate			Total
Tc99m tilmanocept sales revenue:
United States	$	—		$	—		$	—		$	—
International		19,075			—			—			19,075
Tc99m tilmanocept license revenue		1,133,333			—			—			1,133,333
Grant and other revenue		1,860,953			—			—			1,860,953
Total revenue		3,013,361			—			—			3,013,361
Cost of goods sold, excluding depreciation and amortization		3,226			—			—			3,226
Research and development expenses, excluding depreciation and amortization		9,831,834			730,895			—			10,562,729
Selling, general and administrative expenses, excluding depreciation and amortization (a)		—			123,884			10,242,066			10,365,950
Depreciation and amortization (b)		232,091			—			290,105			522,196
Loss from operations (c)		(7,053,790	)		(854,779	)		(10,532,171	)		(18,440,740	)
Other income (expense), excluding equity in the loss of R-NAV, LLC (d)		—			—			(4,298,604	)		(4,298,604	)
Equity in the loss of R-NAV, LLC		—			—			(305,253	)		(305,253	)
L oss from continuing operations		(7,053,790	)		(854,779	)		(15,136,028	)		(23,044,597	)
Income (loss) from discontinued operations, net of tax effect (e)		(5,713,598	)		—			1,194,660			(4,518,938	)
Net loss		(12,767,388	)		(854,779	)		(13,941,368	)		(27,563,535	)
Total assets, net of depreciation and amortization:
United States	$	4,161,029		$	—		$	10,391,805		$	14,552,834
International		410,666			—			1,013			411,679
Capital expenditures		26,589			—			12,412			39,001